An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

• DOI: 10.1126/scitranslmed.aal4291
• Publication Date: 2017-10-04T18:10:37Z
• Authors: Takahiro Ishiguro; Yuji Sano; Shun-ichiro Komatsu; Mika Kamata-Sakurai; Akihisa Kaneko; Yasuko Kinoshita; Hirotake Shiraiwa; Yumiko Azuma; Toshiaki Tsunenari; Yoko Kayukawa; Yukiko Sonobe; Natsuki Ono; Kiyoaki Sakata; Toshihiko Fujii; Yoko Miyazaki; Mizuho Noguchi; Mika Endo; Asako Harada; Werner Frings; Etsuko Fujii; Eitaro Nanba; Atsushi Narita; Akihisa Sakamoto; Tetsuya Wakabayashi; Hiroko Konishi; Hiroaki Segawa; Tomoyuki Igawa; Takashi Tsushima; Hironori Mutoh; Yukari Nishito; Mina Takahashi; Lorraine Stewart; Ehab ElGabry; Yoshiki Kawabe; Masaki Ishigai; Shuichi Chiba; Masahiro Aoki; Kunihiro Hattori; Junichi Nezu
• Keywords: Bispecific antibody; Glypican 3

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody (ERY974) is a promising therapeutic agent for solid tumors.